Targeting the Bromodomain-containing protein 4 in ovarian clear cell carcinoma
Ovarian clear cell carcinoma (OCCC) is the second most common histopathological subtype of ovarian carcinoma (OC), making up 5-25% of all OC. Current treatment utilizing combination chemotherapy with cisplatin and paclitaxel have low efficacy with a 5-year survival rate of only 12%. Bromodomain-cont...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Final Year Project (FYP) |
| Language: | English |
| Published: |
2017
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10356/70625 |